Akebia remains Buy-rated at H.C. Wainwright which sees robust Vafseo demand

Published 15/01/2025, 14:08
Updated 15/01/2025, 16:18
Akebia remains Buy-rated at H.C. Wainwright which sees robust Vafseo demand

On Wednesday, H.C. Wainwright analysts maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA).

The firm's endorsement follows Akebia's announcement on January 13 that the U.S. commercial launch of Vafseo, its treatment for patients with chronic kidney disease (CKD) on dialysis, has commenced with shipments starting on January 9.

The firm reiterated the price target of $7.50 on Akebia stock. Akebia has reported successful commercial supply agreements with a major dialysis organization and a mid-sized provider, ensuring Vafseo is accessible to nearly 100% of U.S. dialysis patients. These agreements are expected to bolster the drug's market presence significantly.

Market research conducted by Akebia suggests a strong demand for Vafseo, with 99% of surveyed U.S. nephrologists open to prescribing the medication.

Furthermore, 75% of these physicians intend to prescribe Vafseo within the first six months of its availability, indicating a positive reception from the medical community.

The potential for Vafseo's use in non-dialysis CKD patients is seen as a significant opportunity for Akebia. The company is focused on finalizing the regulatory pathway for this broader patient population in 2025, which could further enhance the drug's market potential.

Akebia's financial position appears stable, with the management estimating that current cash reserves and projected income will fund operations for at least the next two years.

This includes the commercial launch of Vafseo and the advancement of the company's pipeline. The reaffirmation of the Buy rating and price target by H.C. Wainwright reflects confidence in Akebia's strategy and market prospects for its CKD treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.